COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
Expert commentary on melanoma immunotherapy latest
Vemurafenib for high risk melanoma patients
Nivolumab vs ipilimumab for high risk melanoma patients
ABP 980, a biosimilar antibody for trastuzumab
New strategies in melanoma care
Abemaciclib for advanced breast cancer
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer
CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma
Chemotherapy then surgery no better than concomitant chemoradiation for advanced cervical cancer
MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancer
Financial and ethical safety in cancer care